Latest Regulatory News

Redivium Limited has withdrawn its planned European Green Bond issuance amid challenging market conditions and an ongoing ASX suspension, despite securing conditional investor commitments. The company signals a future return to green debt markets when conditions improve.

Redivium Limited has postponed the completion of its UK lithium-ion battery recycling feasibility study to Q2 2026 due to a site relocation requiring updated environmental assessments. Meanwhile, its European projects in Czechia and Romania continue to advance steadily.

Redivium Limited is advancing a recapitalisation strategy with Australian investors to meet ASX requirements and resume trading after a prolonged suspension.

National Storage REIT has received a conditional, non-binding proposal from a Brookfield and GIC consortium to acquire all stapled securities at $2.86 each, triggering an exclusivity period for negotiations.

ASX Compliance has flagged Rent.com.au Limited for a late filing of a director’s interest change, raising questions about the company’s disclosure controls and compliance with listing rules.

Anatara Lifesciences has completed the final tranche of its placement, issuing over 66 million shares and granting options to its lead manager, marking a key step in its capital raising strategy.

InhaleRX Limited has announced a non-renounceable entitlement offer to raise approximately $247,668 by issuing nearly 10 million new shares at 2.5 cents each, accompanied by free attaching options. The offer opens on 5 December and closes on 17 December 2025.

InhaleRx Limited has introduced SRX-25, an oral fixed-dose combination therapy targeting Treatment-Resistant Depression, aiming to improve patient access and adherence. The company also secured $1 million in capital to advance clinical development and plans a strategic rebrand.

Fulcrum Lithium has secured 201 claims in Nevada’s Lander County, revealing surface lithium grades up to 1,219 ppm and setting the stage for a maiden drilling campaign in early 2026.

PainChek Ltd has secured FDA De Novo clearance for its Adult App, marking a pivotal entry into the US long-term care market and setting the stage for global expansion including its Infant App.

Proteomics International secures a key Medicare reimbursement rate for its PromarkerD test, a predictive diagnostic for diabetic kidney disease, marking a critical step in its US commercial rollout.

Recce Pharmaceuticals has reported compelling preclinical results for its inhaled anti-infective RECCE 327, demonstrating potent activity against multidrug-resistant pneumonia bacteria in mice models.